يحاولGOLD- Free

Invincible Diabetes Turns APAC Into Pharma Goldmine“?
BioSpectrum Asia|November 2022
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes, according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or region specific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.
- Ayesha Siddiqui
Invincible Diabetes Turns APAC Into Pharma Goldmine“?

On October 10, 2022, Chinese firm Hua Medicines snagged the first-in-class nod in China for a diabetes drug Dorzagliatin, a glucokinase activator (GKA). This ends a 10 year drought in type 2 diabetes in terms of lack of ‘medicines with new mechanisms of action’ entering the market. This is welcome news for the region which has 60 per cent of diabetics in the world. It is no wonder then that the largest number of ongoing clinical trials for type 2 diabetes are conducted in the region, with 665 ongoing clinical trials.

Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. The APAC is anticipated to experience considerable growth due to a more geriatric population and rising prevalence of diabetes mainly due to the enhanced stress level, sedentary lifestyles, smoking, and excessive consumption of alcohol that elevates the body’s sugar levels have led to the growth of the market, according to a Mordor Intelligence report.

Moreover, the production basis of certain antidiabetic drug companies in the region also boosted the market growth. However, the increasingly high cost of drugs is considered one of the major restraining factors for the market. According to the Organisation for Economic Cooperation and Development (OECD) iLibrary in APAC, about 227 million people live with type 2 diabetes and about half of them are undiagnosed and unaware of developing long-term complications. Also, according to the International Diabetes Federation (IDF) data, 90 million adults in the age group of 20-79 are living with diabetes in the SouthEast Asia (SEA) Region in 2021 which is projected to increase to 113 million by 2030 and 152 million by 2045.

هذه القصة مأخوذة من طبعة November 2022 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة November 2022 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BIOSPECTRUM ASIA مشاهدة الكل
"We are dedicated to helping people of all ages see brilliantly"
BioSpectrum Asia

"We are dedicated to helping people of all ages see brilliantly"

The global leader in eye care for over 75 years, Alcon Inc. strives to help eye care professionals strengthen their practices and serve patients better, improving visual health worldwide. Through its innovative eye care portfolios, Alcon has established operations in 56 countries and serves patients in 140 countries. Jason Hoffe, Vice President, APAC Vision Care, Alcon, responsible for driving the vision care business in the region shares opportunities exist for the company and new developments in eye healthcare that are cause for optimism for patients in the region.

time-read
5 mins  |
BioSpectrum Asia Jan 2025
Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation
BioSpectrum Asia

Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation

In the current pharmaceutical manufacturing environment, linking information technology (IT) with operational technology (OT) systems is increasingly vital. This integration enables a seamless exchange of information between these two historically separate domains - one focused on data management and the other on overseeing physical operations. This enables various aspects of the manufacturing process to gain insights from one another to boost efficiency and refine strategic decision-making. Digital transformation is essential for directing companies through the complexities of implementation and ensuring a seamless shift to a data-driven, digitally optimized manufacturing landscape.

time-read
6 mins  |
BioSpectrum Asia Jan 2025
Building the Future of Medicine
BioSpectrum Asia

Building the Future of Medicine

PRODUCT OF THE YEAR 2024 - Needle Free Injection System technology by IntegriMedical

time-read
4 mins  |
BioSpectrum Asia Jan 2025
Emerging Leader in Cell & Gene Therapy
BioSpectrum Asia

Emerging Leader in Cell & Gene Therapy

STARTUP OF THE YEAR 2024 - ImmunoACT

time-read
3 mins  |
BioSpectrum Asia Jan 2025
Improving Access for Respiratory Healthcare
BioSpectrum Asia

Improving Access for Respiratory Healthcare

STARTUP OF THE YEAR 2024 - Aevice Health

time-read
4 mins  |
BioSpectrum Asia Jan 2025
Making an Impact with a 'CliKX'
BioSpectrum Asia

Making an Impact with a 'CliKX'

Dr Lynne Lim, Co-Founder & Chief Executive Officer, NousQ

time-read
4 mins  |
BioSpectrum Asia Jan 2025
Eyeing 20-20 Vision of Excellence
BioSpectrum Asia

Eyeing 20-20 Vision of Excellence

Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research

time-read
4 mins  |
BioSpectrum Asia Jan 2025
Refining the Use of Radiation
BioSpectrum Asia

Refining the Use of Radiation

Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals

time-read
3 mins  |
BioSpectrum Asia Jan 2025
Honouring Innovators in Asia's Thriving Life Sciences Sector
BioSpectrum Asia

Honouring Innovators in Asia's Thriving Life Sciences Sector

Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.

time-read
2 mins  |
BioSpectrum Asia Jan 2025
How To Control Indian Diabetes Growth
BioSpectrum Asia

How To Control Indian Diabetes Growth

World Diabetes Day, observed on November 14, reminds us of the growing impact of diabetes on global health and the urgent need for collective action to prevent, diagnose, and manage this chronic condition. In 2024, the theme 'Breaking Barriers, Bridging Gaps' underscores the critical importance of accessible, high-quality diabetes care, especially for underrepresented communities. The Government of India has taken many measures intending to reduce the prevalence of diabetes and alleviate its long-term complications, contributing to a healthier future for all citizens.

time-read
4 mins  |
December 2024

نحن نستخدم ملفات تعريف الارتباط لتقديم خدماتنا وتحسينها. باستخدام موقعنا ، فإنك توافق على ملفات تعريف الارتباط. يتعلم أكثر